The Role of Inflammasomes in Heart Failure
暂无分享,去创建一个
P. Theofilis | M. Drakopoulou | A. Kordalis | Panayotis K. Vlachakis | I. Leontsinis | A. Apostolos | P. Vlachakis | K. Tsioufis | Dimitris Tousoulis | Ioannis Kachrimanidis | Konstantinos Giannakopoulos
[1] M. D. de Borst,et al. Increased interleukin-6 is associated with higher risk of heart failure in people with type 2 diabetes. , 2024, ESC heart failure.
[2] C. Jonasson,et al. Association of inflammatory markers with incident heart failure or cancer in the HUNT3 and Health ABC population studies. , 2024, European journal of preventive cardiology.
[3] F. Vasques-Nóvoa,et al. Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study. , 2024, Atherosclerosis.
[4] Xiao-cheng Cheng,et al. NLRP3-inflammasome inhibition by MCC950 attenuates cardiac and pulmonary artery remodelling in heart failure with preserved ejection fraction. , 2023, Life sciences.
[5] A. Manolis,et al. Neurohumoral Activation in Heart Failure , 2023, International journal of molecular sciences.
[6] D. Tousoulis,et al. Inflammasomes in Atherosclerosis—From Pathophysiology to Treatment , 2023, Pharmaceuticals.
[7] P. Ridker,et al. Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction. , 2023, JACC. Heart failure.
[8] J. Coresh,et al. Association of Interleukin-6 and Interleukin-18 with Cardiovascular Disease in Older Adults: Atherosclerosis Risk in Communities Study. , 2023, European journal of preventive cardiology.
[9] I. Mourouzis,et al. SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century? , 2023, Nutrients.
[10] J. McMurray,et al. Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction , 2023, Circulation. Heart failure.
[11] Gang Liu,et al. Burden, Trends, and Inequalities of Heart Failure Globally, 1990 to 2019: A Secondary Analysis Based on the Global Burden of Disease 2019 Study , 2023, Journal of the American Heart Association.
[12] S. Prabhu,et al. Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation , 2023, Circulation research.
[13] A. von Eckardstein,et al. Quantifying inflammation using interleukin‐6 for improved phenotyping and risk stratification in acute heart failure , 2023, European journal of heart failure.
[14] Shan Liu,et al. The selective NLRP3 inflammasome inhibitor MCC950 improves isoproterenol-induced cardiac dysfunction by inhibiting cardiomyocyte senescence. , 2022, European journal of pharmacology.
[15] A. Leite-Moreira,et al. Interleukin-6, infection and cardiovascular outcomes in acute heart failure: Findings from the EDIFICA registry. , 2022, Cytokine.
[16] Yuting Feng,et al. Colchicine Ameliorates Dilated Cardiomyopathy Via SIRT2‐Mediated Suppression of NLRP3 Inflammasome Activation , 2022, Journal of the American Heart Association.
[17] L. Kang,et al. Colchicine alleviates inflammation and improves diastolic dysfunction in heart failure rats with preserved ejection fraction. , 2022, European journal of pharmacology.
[18] Jianfang Liu,et al. MCC950, a Selective NLRP3 Inhibitor, Attenuates Adverse Cardiac Remodeling Following Heart Failure Through Improving the Cardiometabolic Dysfunction in Obese Mice , 2022, Frontiers in Cardiovascular Medicine.
[19] E. Roselló-Lletí,et al. Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models , 2022, International journal of molecular sciences.
[20] Liyuan Zhu,et al. Emerging Roles of Inflammasomes in Cardiovascular Diseases , 2022, Frontiers in Immunology.
[21] M. Link,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.
[22] F. Yang,et al. MCC950 ameliorates ventricular arrhythmia vulnerability induced by heart failure , 2022, Bioengineered.
[23] P. Aukrust,et al. Targeting the Inflammasome in Cardiovascular Disease , 2021, JACC. Basic to translational science.
[24] Han Xiao,et al. The Role of the Inflammasome in Heart Failure , 2021, Frontiers in Physiology.
[25] P. Secchiero,et al. Autoinflammatory Diseases and Cytokine Storms—Imbalances of Innate and Adaptative Immunity , 2021, International journal of molecular sciences.
[26] Jianfang Liu,et al. Selective Inhibition of NLRP3 Inflammasome Reverses Pressure Overload-Induced Pathological Cardiac Remodeling by Attenuating Hypertrophy, Fibrosis, and Inflammation. , 2021, International immunopharmacology.
[27] Z. Giricz,et al. AIM2-driven inflammasome activation in heart failure. , 2021, Cardiovascular research.
[28] A. Abbate,et al. Preservation of Contractile Reserve and Diastolic Function by Inhibiting the NLRP3 Inflammasome with OLT1177® (Dapansutrile) in a Mouse Model of Severe Ischemic Cardiomyopathy Due to Non-Reperfused Anterior Wall Myocardial Infarction , 2021, Molecules.
[29] Hua Zhu,et al. Gasdermin D in pyroptosis , 2021, Acta pharmaceutica Sinica. B.
[30] Ming Xu,et al. Membrane nanotubes facilitate the propagation of inflammatory injury in the heart upon overactivation of the β-adrenergic receptor , 2020, Cell Death & Disease.
[31] J. Canada,et al. Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II–III Systolic Heart Failure , 2020, Journal of cardiovascular pharmacology.
[32] Zhi-Sheng Jiang,et al. Emerging roles of absent in melanoma 2 in cardiovascular diseases. , 2020, Clinica chimica acta; international journal of clinical chemistry.
[33] S. Nattel,et al. Atrial Myocyte NLRP3/CaMKII Nexus Forms a Substrate for Postoperative Atrial Fibrillation , 2020, Circulation research.
[34] Shiqi Yang,et al. Pyroptosis: a pro-inflammatory type of cell death in cardiovascular disease. , 2020, Clinica chimica acta; international journal of clinical chemistry.
[35] B. V. Van Tassell,et al. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease , 2020, Circulation research.
[36] Jia Hu,et al. NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy , 2020, Redox biology.
[37] C. McCarthy,et al. Inflammation in Heart Failure: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.
[38] Xiao-yu Liu,et al. Blockade of β-adrenergic signaling suppresses inflammasome and alleviates cardiac fibrosis. , 2020, Annals of translational medicine.
[39] D. Mann,et al. Reappraising the role of inflammation in heart failure , 2020, Nature Reviews Cardiology.
[40] Hongshan Chen,et al. SNO-MLP (S-Nitrosylation of Muscle LIM Protein) Facilitates Myocardial Hypertrophy Through TLR3 (Toll-Like Receptor 3)–Mediated RIP3 (Receptor-Interacting Protein Kinase 3) and NLRP3 (NOD-Like Receptor Pyrin Domain Containing 3) Inflammasome Activation , 2020, Circulation.
[41] Lei Xu,et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. , 2019, International immunopharmacology.
[42] C. Ferrario,et al. NLRP3 inhibition improves heart function in GPER knockout mice. , 2019, Biochemical and biophysical research communications.
[43] J. Ting,et al. The NLRP3 inflammasome: molecular activation and regulation to therapeutics , 2019, Nature Reviews Immunology.
[44] Antoni Bayes-Genis,et al. The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure. , 2019, Journal of the American College of Cardiology.
[45] Jinyu Pan,et al. AIM2 gene silencing attenuates diabetic cardiomyopathy in type 2 diabetic rat model , 2019, Life sciences.
[46] S. Miyamoto,et al. Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca2+/Calmodulin-Dependent Protein Kinase II &dgr; Signaling in Cardiomyocytes Are Essential for Adverse Cardiac Remodeling , 2018, Circulation.
[47] Corey L. Reynolds,et al. Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation , 2018, Circulation.
[48] S. Nasoohi,et al. MCC950, the Selective Inhibitor of Nucleotide Oligomerization Domain-Like Receptor Protein-3 Inflammasome, Protects Mice against Traumatic Brain Injury. , 2018, Journal of neurotrauma.
[49] K. Otsu,et al. Mitochondria and sterile inflammation in the heart , 2018 .
[50] D. Tousoulis,et al. The Role of Colchicine in Pericardial Syndromes. , 2018, Current pharmaceutical design.
[51] S. Ylä-Herttuala,et al. Aggravated Postinfarct Heart Failure in Type 2 Diabetes Is Associated with Impaired Mitophagy and Exaggerated Inflammasome Activation. , 2017, The American journal of pathology.
[52] J. Bauersachs,et al. Immune mechanisms in heart failure , 2017, European journal of heart failure.
[53] F. Roubille,et al. Interest of colchicine in the treatment of acute myocardial infarct responsible for heart failure in a mouse model. , 2017, International journal of cardiology.
[54] J. Butler,et al. ASC Methylation and Interleukin-1&bgr; Are Associated with Aerobic Capacity in Heart Failure , 2017, Medicine and science in sports and exercise.
[55] M. Ishii,et al. Colchicine Improves Survival, Left Ventricular Remodeling, and Chronic Cardiac Function After Acute Myocardial Infarction. , 2017, Circulation journal : official journal of the Japanese Circulation Society.
[56] Dacheng Wang,et al. Pore-forming activity and structural autoinhibition of the gasdermin family , 2016, Nature.
[57] Jagmeet P. Singh,et al. Inflammatory Mediators and Clinical Outcome in Patients With Advanced Heart Failure Receiving Cardiac Resynchronization Therapy. , 2016, The American journal of cardiology.
[58] Si Ming Man,et al. Regulation of inflammasome activation , 2015, Immunological reviews.
[59] Sky W. Brubaker,et al. Innate immune pattern recognition: a cell biological perspective. , 2015, Annual review of immunology.
[60] Wei Wu,et al. A meta-analysis of proinflammatory cytokines in chronic heart failure , 2014, Heart Asia.
[61] M. Cleman,et al. Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. , 2014, JACC. Heart failure.
[62] Fan Wang,et al. Association of nucleotide-binding oligomerization domain-like receptor 3 inflammasome and adverse clinical outcomes in patients with idiopathic dilated cardiomyopathy , 2013, Clinical chemistry and laboratory medicine.
[63] N. Frangogiannis,et al. The pathogenesis of cardiac fibrosis , 2013, Cellular and Molecular Life Sciences.
[64] S. Bunn,et al. Cytokine Interactions with Adrenal Medullary Chromaffin Cells , 2010, Cellular and Molecular Neurobiology.
[65] S. Anker,et al. Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. , 2009, Heart failure clinics.
[66] H. Shimokawa,et al. Colchicine, a microtubule depolymerizing agent, inhibits myocardial apoptosis in rats. , 2007, The Tohoku journal of experimental medicine.
[67] H. Okamura,et al. Increased circulating interleukin-18 in patients with congestive heart failure , 2002, Heart.
[68] M. Yamaoka-Tojo,et al. Circulating levels of interleukin 18 reflect etiologies of heart failure: Th1/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. , 2002, Journal of cardiac failure.
[69] S. Anker,et al. Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.
[70] D. Grobbee,et al. An epidemic of heart failure? Recent evidence from Europe. , 1998, European heart journal.
[71] G. P. V. van Hout,et al. The Inflammasomes in Cardiovascular Disease. , 2018, Experientia supplementum.
[72] W. Gao,et al. IL-18 cleavage triggers cardiac inflammation and fibrosis upon &bgr;-adrenergic insult , 2018, European heart journal.
[73] B. Borlaug. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction. , 2014, Circulation journal : official journal of the Japanese Circulation Society.
[74] C. H. Conrad,et al. Direct effects of colchicine on myocardial function: studies in hypertrophied and failing spontaneously hypertensive rats. , 1999, Hypertension.
[75] G. Bonsel,et al. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. , 1994, American journal of public health.